PRESS RELEASE published on 04/03/2025 at 07:00, 1 year 7 months ago “Tunnel Ostbahnhof” joint venture awarded contract for eastern section of the Second Core S-Bahn Route in Munich Implenia AG's joint venture awarded major contract for 'Tunnel Ostbahnhof' project as part of the Second Core S-Bahn Route in Munich, worth hundreds of millions of euros. Construction begins in June 2025 and aims for completion by May 2033 Implenia AG Munich Deutsche Bahn Tunnel Ostbahnhof Second Core S-Bahn Route
PRESS RELEASE published on 04/03/2025 at 07:00, 1 year 7 months ago Holcim acquires Compañía Minera Luren to expand in Latin America Holcim acquires Compañía Minera Luren, leading Peruvian producer of high-value building solutions, to expand in Latin America and accelerate growth. Acquisition expected to generate synergies in Peru and Latin America Acquisition Latin America Holcim Building Solutions Compañía Minera Luren
PRESS RELEASE published on 04/03/2025 at 07:00, 1 year 7 months ago Multitude AG Preliminary Unaudited 2024 Results Highlighting Strong Growth and Profitability Multitude AG reports preliminary unaudited 2024 results with 14.4% revenue growth to EUR 263.7 million and 48.5% jump in EBIT to EUR 67.6 million. Strong profitability demonstrated Revenue Growth Financial Performance Profitability Preliminary Results Multitude AG
PRESS RELEASE published on 04/03/2025 at 07:00, 1 year 7 months ago Communiqué de presse : Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de deux maladies rares contre lesquelles il n’existe aucun médicament approuvé Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de deux maladies rares, l'anémie hémolytique à anticorps chauds et la maladie associée aux IgG4, sans traitement approuvé actuellement FDA Traitement Maladies Rares Médicament Orphelin Rilzabrutinib
PRESS RELEASE published on 04/03/2025 at 07:00, 1 year 7 months ago Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Rilzabrutinib granted orphan drug designation in the US for warm autoimmune hemolytic anemia and IgG4-related disease, potential use in immune thrombocytopenia. Sanofi's novel BTK inhibitor holds promise for rare diseases Orphan Drug Designation Sanofi Rare Diseases Rilzabrutinib BTK Inhibitor
PRESS RELEASE published on 04/03/2025 at 06:59, 1 year 7 months ago grenke achieves very profitable new business in Q1 2025 grenke AG reports a 10.6% growth in leasing new business to EUR 740.6 million and a 15.6% increase in Contribution Margin 2 in Q1 2025, aiming to enhance profitability and market leadership Profitability Leasing GRENKE AG New Business CM2
PRESS RELEASE published on 04/03/2025 at 06:59, 1 year 7 months ago Aperam update on Q1 2025 market & financial trends Aperam provides an update on Q1 2025 market & financial trends ahead of the quarterly results release. Details on EBITDA, acquisitions, cash flow, and market outlook included Market Trends Aperam Earnings Guidance Financial Update Q1 2025
PRESS RELEASE published on 04/03/2025 at 06:59, 1 year 7 months ago Aperam update on Q1 2025 market & financial trends Aperam provides update on Q1 2025 market & financial trends including adjusted EBITDA, pricing pressure, net debt, and operational highlights Aperam Market Update Financial Trends Q1 2025 Earnings Drivers
PRESS RELEASE published on 04/03/2025 at 06:40, 1 year 7 months ago Ad hoc announcement pursuant to Art. 53 LR: Jungfraubahn Holding AG: Jungfrau Railway Group reports a successful 2024 financial year Jungfraubahn Holding AG announces a successful 2024 financial year with increased transport income and proposal to raise dividend. Jungfraujoch and Experience Mountains segments show strong performance Dividend Proposal Jungfraubahn Holding AG 2024 Financial Year Segment Performance Transport Income
PRESS RELEASE published on 04/03/2025 at 05:10, 1 year 7 months ago Battery X Metals Announces Corporate Awareness Agreement Battery X Metals Inc. engages bullVestor for marketing services to increase awareness among European investment community. Explore more at batteryxmetals.com Energy Transition Marketing Services Battery X Metals European Investment BullVestor
Published on 11/10/2026 at 14:31, 5 hours 14 minutes ago First Breach Plans to Integrate Onboard AI Computing into CQS and LRS Drone Platforms
Published on 11/10/2026 at 14:30, 5 hours 15 minutes ago Stabilis Solutions Announces Three-Year Take-Or-Pay LNG Supply Agreement with Existing Aerospace Customer
Published on 11/10/2026 at 14:30, 5 hours 15 minutes ago ACCESS Newswire Reports Third Quarter 2026 Results
Published on 11/10/2026 at 14:00, 5 hours 45 minutes ago Horizon Aircraft Completes Preliminary Design Review of Cavorite X7 Hybrid eVTOL
Published on 11/10/2026 at 19:21, 23 minutes ago ALTHEORA, Mäder Composites France et IPC s'associent pour donner une seconde vie aux matériaux composites
Published on 11/10/2026 at 18:54, 50 minutes ago REPLOID Group AG pursues entry in the US market and secures exclusivity to conduct due diligence for the potential acquisition of Chapul, LLC.
Published on 11/10/2026 at 18:45, 1 hour ago Special Optics Introduces Purpose-Built Microscope Objectives for Quantum Applications
Published on 11/10/2026 at 18:30, 1 hour 15 minutes ago Shelly Group Accelerates Revenue Growth in the Third Quarter and Confirms Full-Year 2026 Guidance
Published on 11/10/2026 at 18:00, 1 hour 45 minutes ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:35, 2 hours 10 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 2 hours 13 minutes ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.